Design, Synthesis and Biological Evaluations of Diverse Michael Acceptor-Based Phenazine Hybrid Molecules As TrxR1 Inhibitors.

Yucheng Zhong,Jing Liu,Xiangyu Cheng,Hao Zhang,Chunhua Zhang,Zhuolu Xia,Zhongxi Wu,Lu Zhang,Yuting Zheng,Zhanyu Gao,Zhidong Jiang,Zhixiang Wang,Dechun Huang,Yuanyuan Lu,Feng Jiang
DOI: https://doi.org/10.1016/j.bioorg.2021.104736
IF: 5.307
2021-01-01
Bioorganic Chemistry
Abstract:A series of novel phenazine derivatives (1 similar to 27) containing the Michael acceptor scaffolds were designed and synthesized in this study. Some compounds exhibited selective cytotoxicity against Bel-7402 cancer cell line in vitro, in which compound 26 were found to have the best antiproliferative activity. Meanwhile, compound 26 showed no obvious cell toxicity against human normal liver epithelial L02 cells, which means this compound possessed a better safety potential. In the following research, compound 26 was verified to inhibit TrxR1 enzyme activity, ultimately resulting in cellular molecular mechanism events of apoptosis including growth of intracellular ROS level, depletion of reduced Trx1, liberation of ASK1 and up-regulation of p38, respectively. Together, all these evidences implicated that compound 26 acted as the TrxR1 inhibitor against Bel-7402 cells, and could activate apoptosis through the ROS-Trx-ASK1-p38 pathway.
What problem does this paper attempt to address?